CAPASTAT SULFATE (capreomycin sulfate) by Fosun Pharma. Approved for tuberculosis. First approved in 1971.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
CAPASTAT SULFATE (capreomycin sulfate) is an injectable antimycobacterial antibiotic approved in 1971 for treatment of tuberculosis, particularly drug-resistant strains. It is administered via intramuscular or intravenous injection as part of combination therapy regimens. The drug inhibits bacterial protein synthesis and is reserved for cases where first-line TB agents are ineffective or contraindicated.
Product is in mature/declining phase with limited growth trajectory; commercial teams likely focused on retention and managed care negotiations rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
CAPASTAT SULFATE offers limited traditional pharma career growth; opportunities exist primarily in specialty markets, global health organizations, and generic/contract manufacturing serving endemic TB regions. This product is suited for professionals passionate about infectious disease and underserved populations rather than those seeking rapid advancement in growth-stage commercialization.
Worked on CAPASTAT SULFATE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.